Enfortumab Vedotin Ejfv

Drug Overview

Enfortumab vedotin ejfv is an Antibody-Drug Conjugate (ADC) that targets Nectin-4, an adhesion protein highly expressed on the surface of most urothelial cancer cells. By delivering a potent cytotoxic payload directly to the tumor, it is a highly selective form of Targeted Therapy and a Smart Drug.

• Generic Name: Enfortumab vedotin ejfv
• US Brand Names: Padcev®
• Drug Class: Antibody-Drug Conjugate (ADC), Nectin-4 Directed Agent
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Approved for the treatment of locally advanced or metastatic urothelial cancer (UC).

What Is It and How Does It Work? (Mechanism of Action)

Enfortumab vedotin is a complex molecule consisting of three parts: a monoclonal antibody, a cleavable linker, and a potent microtubule-disrupting agent (monomethyl auristatin E, or MMAE). This structure allows for precise, targeted delivery of the cytotoxic payload.

• Molecular Target (Nectin-4): The antibody component of the ADC specifically binds to Nectin-4, an adhesion molecule that is frequently and highly overexpressed on urothelial cancer cells.
• Action (Internalization): Once bound to the Nectin-4 protein on the cell surface, the entire complex (antibody-linker-drug) is internalized by the cancer cell via endocytosis.
• Result (Microtubule Disruption and Apoptosis): MMAE is a potent microtubule-disrupting agent. By interfering with the microtubule network, it inhibits cell division (mitosis), leading to cell cycle arrest in the G2/M phase and subsequent apoptosis (programmed cell death) of the cancer cell. The precision of the delivery mechanism minimizes systemic exposure to the chemotherapy agent.
• Bone Affinity: Not applicable. Enfortumab vedotin is a systemic targeted therapy and does not possess selective affinity for bone components.

FDA Approved Clinical Indications

Enfortumab vedotin is a foundational treatment for advanced urothelial cancer, particularly in the post-platinum and post-checkpoint inhibitor settings.

Oncological Uses

1. Locally Advanced or Metastatic Urothelial Cancer (UC): Indicated for patients who have previously received a platinum-containing chemotherapy regimen and a programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) inhibitor.
2. Cisplatin-Ineligible UC: Approved in combination with Pembrolizumab for first-line treatment of patients with locally advanced or metastatic UC who are ineligible for cisplatin-containing chemotherapy.

Non-oncological Uses

1. There are currently no FDA-approved non-oncological indications for Enfortumab vedotin-ejfv.
2. Its mechanism is strictly targeted to cancer cells overexpressing Nectin-4.

Dosage and Administration Protocols

Enfortumab vedotin is administered on a cyclical, repeated schedule. It is crucial to adhere to the recommended infusion rates to prevent infusion-related reactions.

• Dose Reduction: Dose reduction is required for managing specific adverse events, notably severe skin reactions, severe peripheral neuropathy, or persistent Grade 3/4 hyperglycemia. The dose can be reduced to 1.0 milligram per kilogram and subsequently to 0.75 milligram per kilogram.
• Renal Insufficiency: No dose adjustment is required for mild to severe renal impairment.
• Hepatic Insufficiency: No dose adjustment is required for mild hepatic impairment. Use is not recommended for moderate or severe hepatic impairment due to increased MMAE exposure and risk of toxicity.

Standard Dosing for Oncological Indications (Urothelial Cancer)

Clinical Efficacy and Research Results

Enfortumab vedotin has become a standard-of-care agent based on trials demonstrating significant improvements in survival in a heavily pre-treated patient population.

• Metastatic UC (EV-301 Trial – 2020-2025 Context): This Phase III trial compared Enfortumab vedotin to physician’s choice chemotherapy (Taxanes or Vinflunine) in previously treated patients.
• Overall Survival (OS): Enfortumab vedotin significantly improved median OS to 12.88 months compared to 8.97 months for chemotherapy, representing a 30 percent reduction in the risk of death (Hazard Ratio of 0.70).
• Objective Response Rate (ORR): The ORR was 40.6 percent versus 17.9 percent for chemotherapy.
• First-Line Cisplatin-Ineligible UC (EV-103/KEYNOTE-869 Trial): In combination with Pembrolizumab, the ORR was remarkably high, reaching 68 percent, with a complete response (CR) rate of 31 percent, indicating deep and durable responses.

Safety Profile and Side Effects

Black Box Warning

The toxicity profile is distinct, marked by dermatological reactions, peripheral neuropathy (due to MMAE), and a significant risk of hyperglycemia.

Common Side Effects (> 10 percent)

• Dermatological: Rash (very common, may be severe, including maculopapular, pruritic, or exfoliative).
• Neurological: Peripheral neuropathy (numbness, tingling, or weakness in hands/feet) (due to MMAE).
• Gastrointestinal: Fatigue, alopecia (hair loss), diarrhea, decreased appetite.

Serious Adverse Events

1. Severe Cutaneous Reactions: Rare but potentially life-threatening skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
2. Hyperglycemia: Severe and sometimes fatal hyperglycemia or diabetic ketoacidosis, particularly in patients with pre-existing diabetes.
3. Peripheral Neuropathy: Persistent or Grade 3/4 sensory or motor neuropathy, requiring dose delay or discontinuation.

Connection to Stem Cell and Regenerative Medicine

Enfortumab vedotin’s mechanism of action is supportive of regenerative principles by providing highly localized cytotoxicity while offering options for patients who have exhausted traditional systemic therapies.

• Localized Cytotoxicity: The ADC platform delivers chemotherapy specifically to the Nectin-4 expressing cells, sparing most healthy cells. This protective action is critical for minimizing damage to hematopoietic stem cells and other rapidly dividing normal tissues, thus preserving the body’s natural regenerative capacity.
• Bridging to Other Therapies: For patients with relapsed/refractory UC, achieving a durable response with Enfortumab vedotin can potentially render them fit enough for future curative-intent procedures, including surgery or possible cellular therapies under investigation.

Patient Management and Practical Recommendations 

Pre-treatment Tests to Be Performed

Patient education regarding the unique risks of skin reactions, blood sugar control, and neuropathy is paramount.

• Blood Glucose: Baseline hemoglobin A1c and fasting blood glucose are mandatory.
• Neurological Assessment: Baseline neurological exam to assess for pre-existing peripheral neuropathy.

Precautions During Treatment

• Glucose Monitoring: Patients must monitor blood glucose levels closely (daily for diabetics) and be managed aggressively for any increases.
• Skin Monitoring: Instruct patients to immediately report any new or worsening rash or skin blistering.

Do’s and Don’ts List

• DO report any new skin rash, blistering, or peeling immediately to your care team.
• DO report any numbness, tingling, or difficulty buttoning clothes (signs of neuropathy).
• DON’T miss scheduled appointments for lab work, including blood glucose and liver tests.
• DON’T ignore foot or hand numbness, as this may lead to permanent motor or sensory damage.

Legal Disclaimer

The information provided herein regarding Enfortumab vedotin-ejfv (Padcev®) is intended for general informational purposes only and is directed towards an international audience of patients and healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or personalized treatment from a qualified oncologist. This drug involves severe risks including hyperglycemia, peripheral neuropathy, and potentially fatal skin reactions. All individuals must consult their specific healthcare provider for information tailored to their medical condition and treatment regimen. Reliance on any information appearing on this guide is solely at your own risk.